Options for Treating the High-Risk APL Patient

Alan Burnett, MD, takes a look at the combination of ATRA + ATO + GO in high-risk acute promyelocytic leukemia (APL) patients, the complications that APL patients face, and moving away from chemotherapy. For more on these results, read our coverage of the study here.

SHARE